Beijing SL Pharmaceutical Co Ltd (002038) - Total Liabilities
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has total liabilities worth CN¥735.46 Million CNY (≈ $107.62 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 002038 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Beijing SL Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Beijing SL Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Beijing SL Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Annexon Inc
NASDAQ:ANNX
|
USA | $58.35 Million |
|
Barclays PLC
LSE:BARC
|
UK | GBX1.62 Trillion |
|
PPHE Hotel Group Ltd
F:32P
|
Germany | €1.40 Billion |
|
Bravura Solutions Ltd
AU:BVS
|
Australia | AU$94.57 Million |
|
Pexip Holding ASA
OL:PEXIP
|
Norway | Nkr508.69 Million |
|
WEB Travel Group Ltd
AU:WEB
|
Australia | AU$961.70 Million |
|
Mesnac Co Ltd
SHE:002073
|
China | CN¥13.87 Billion |
|
JOST Werke AG
XETRA:JST
|
Germany | €1.27 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Beijing SL Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Beijing SL Pharmaceutical Co Ltd (002038) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing SL Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing SL Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Beijing SL Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥883.49 Million ≈ $129.28 Million |
+121.78% |
| 2024-12-31 | CN¥398.37 Million ≈ $58.29 Million |
-14.83% |
| 2023-12-31 | CN¥467.72 Million ≈ $68.44 Million |
+17.93% |
| 2022-12-31 | CN¥396.60 Million ≈ $58.04 Million |
-8.67% |
| 2021-12-31 | CN¥434.23 Million ≈ $63.54 Million |
+5.89% |
| 2020-12-31 | CN¥410.09 Million ≈ $60.01 Million |
+1.57% |
| 2019-12-31 | CN¥403.76 Million ≈ $59.08 Million |
-14.05% |
| 2018-12-31 | CN¥469.73 Million ≈ $68.74 Million |
+64.43% |
| 2017-12-31 | CN¥285.67 Million ≈ $41.80 Million |
+88.95% |
| 2016-12-31 | CN¥151.19 Million ≈ $22.12 Million |
+1.88% |
| 2015-12-31 | CN¥148.40 Million ≈ $21.72 Million |
+7.60% |
| 2014-12-31 | CN¥137.92 Million ≈ $20.18 Million |
+12.05% |
| 2013-12-31 | CN¥123.09 Million ≈ $18.01 Million |
+17.04% |
| 2012-12-31 | CN¥105.17 Million ≈ $15.39 Million |
+108.19% |
| 2011-12-31 | CN¥50.52 Million ≈ $7.39 Million |
+35.72% |
| 2010-12-31 | CN¥37.22 Million ≈ $5.45 Million |
+1.28% |
| 2009-12-31 | CN¥36.75 Million ≈ $5.38 Million |
+41.86% |
| 2008-12-31 | CN¥25.91 Million ≈ $3.79 Million |
-25.36% |
| 2007-12-31 | CN¥34.71 Million ≈ $5.08 Million |
-1.98% |
| 2006-12-31 | CN¥35.41 Million ≈ $5.18 Million |
+51.19% |
| 2005-12-31 | CN¥23.42 Million ≈ $3.43 Million |
-17.47% |
| 2004-12-31 | CN¥28.38 Million ≈ $4.15 Million |
-22.84% |
| 2003-12-31 | CN¥36.78 Million ≈ $5.38 Million |
+113.50% |
| 2002-12-31 | CN¥17.23 Million ≈ $2.52 Million |
+58.96% |
| 2001-12-31 | CN¥10.84 Million ≈ $1.59 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more